EUVIMEDEUVIMED entdecken
Crossref

GLP ‐1 agonists for people living with HIV and obesity, is there a potential?

L Zino iD, C J Tack, O Richel, D M Burger iD

HIV Medicine · 2023

DOI: 10.1111/hiv.13521 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2023. Verfasst von L Zino und 3 weiteren Autor:innen. Beteiligte Einrichtung: Radboud University Medical Center, Department of Pharmacy and Radboudumc Research Institute for Medical Innovation (RIMI), Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, HIV Infections. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Obesity trends and metabolic dysregulation are rising in people living with HIV using antiretrovirals (ARVs). Underlying causes and preventive strategies are being investigated. Two glucagon like‐peptide 1 (GLP‐1) agonists, liraglutide and semaglutide, were formerly approved as glucose‐lowering drugs and have been recently approved for long‐term weight loss in people with obesity. Due to the lack of therapeutic guidelines or clinical trials in people with HIV, we discuss the potential benefits, safety aspects and pharmacological considerations of prescribing liraglutide and semaglutide in people with HIV.

Results

Clinical experience is limited to two clinical cases of diabetic people with HIV using liraglutide after which a successful weight loss and glycaemic control were observed. None of the adverse events associated with liraglutide and semaglutide usage indicate an additional risk for people with HIV. Extra caution showed be warranted when initiating GLP‐1 agonist therapy in people with HIV taking protease inhibitors who have pre‐existing risk factors for heart rate variability to reduce the incidence of RP interval prolongation. GLP‐1 agonists are metabolized by endopeptidases, and thus do not generate major drug–drug interactions with most drugs, including ARVs. GLP‐s agonists are known to inhibit gastric acid secretion, which warrants caution and close monitoring when combined with atazanavir and oral rilpivirine, two ARVs that require low gastric pH for an optimal absorption.

Conclusion

Theoretical considerations and a few available clinical observations support semaglutide and liraglutide prescription in people with HIV, with, thus far, no indications of concern regarding efficacy, safety or pharmacological interactions with ARVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HIV InfectionsHumansLiraglutideHypoglycemic AgentsGlucagon-Like Peptide 1ObesityWeight Loss

Stichwörter der Autor:innen

GLP-1 agonistHIVliraglutideobesitysemaglutide

Substanzen

LiraglutideHypoglycemic AgentsGlucagon-Like Peptide 1

Autor:innen und Institutionen

  • Radboud University Medical Center, Department of Pharmacy and Radboudumc Research Institute for Medical Innovation (RIMI), Nijmegen, The Netherlands.
  • Radboud University Medical Center, Department of Internal Medicine and Radboudumc Research Institute for Medical Innovation (RIMI), Nijmegen, The Netherlands.

ORCID-Profile: L Zino, D M Burger

Zitieren

APA

Zino, L., Tack, C. J., Richel, O., & Burger, D. M. (2023). GLP ‐1 agonists for people living with HIV and obesity, is there a potential?. HIV Medicine. https://doi.org/10.1111/hiv.13521

Vancouver

Zino L, Tack CJ, Richel O, Burger DM. GLP ‐1 agonists for people living with HIV and obesity, is there a potential?. HIV Medicine. 2023. doi:10.1111/hiv.13521

BibTeX
@article{Zino2023,
  author = {Zino, L and Tack, C J and Richel, O and Burger, D M},
  title = {GLP ‐1 agonists for people living with HIV and obesity, is there a potential?},
  journal = {HIV Medicine},
  year = {2023},
  doi = {10.1111/hiv.13521}
}
Kostenlos starten →